In the last three months, 4 analysts have published ratings on Vanda Pharmaceuticals (NASDAQ:VNDA), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Vanda Pharmaceuticals, revealing an average target of $16.88, a high estimate of $24.00, and a low estimate of $7.50. Marking an increase of 16.41%, the current average surpasses the previous average price target of $14.50.
Exploring Analyst Ratings: An In-Depth Overview
A comprehensive examination of how financial experts perceive Vanda Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $24.00 | $22.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $22.00 | $20.00 |
| Madison El-Saadi | B. Riley Securities | Raises | Buy | $14.00 | $11.00 |
| Chris Howerton | Jefferies | Raises | Hold | $7.50 | $5.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Vanda Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vanda Pharmaceuticals compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Vanda Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Vanda Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Vanda Pharmaceuticals analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Understanding the Numbers: Vanda Pharmaceuticals's Finances
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Vanda Pharmaceuticals's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 18.06%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -40.15%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.74%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Vanda Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.68%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Vanda Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
The Significance of Analyst Ratings Explained
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
- No comments yet. Be the first to comment!